 |
BioCryst Pharmaceuticals BCRX (news,
chart,
quote) - BCRX option implied volatility collapses to 65 from 81
BCRX is up 3.31 to 15.08. BCRX and Roche announced they will collaborate on clinical compound BCX-4208, for the prevention of acute rejection in transplantation and the treatment of autoimmune diseases. WEDB reiterated their Buy rating and $17 price target on BCRX. BCRX December option implied volatility of 65 is below a level of 81 from yesterday. BCRX intra-day call option volume of 8,318 contracts compares to intra-day put volume of 835 contracts. Decreasing option implied volatility suggest reduced price fluctuations & risk.
|
|
|
|
